From the FDA Drug Label
Additional pediatric use information is approved for Otsuka America Pharmaceutical, Inc.'s ABILIFY ® (aripiprazole) product. ABILIFY ® is a trademark of Otsuka Pharmaceutical Company.
The trade name for Aripiprazole is Abilify 1.
From the Research
The trade name for Aripiprazole is Abilify. Aripiprazole is an atypical antipsychotic medication commonly prescribed to treat conditions such as schizophrenia, bipolar disorder, major depressive disorder, and irritability associated with autism. It works by helping to restore the balance of certain natural chemicals in the brain (neurotransmitters), particularly dopamine and serotonin. Abilify is available in various formulations including tablets, orally disintegrating tablets, oral solution, and injectable forms. The medication is typically taken once daily, with dosages varying based on the condition being treated and individual patient factors. Common side effects may include weight gain, restlessness, and dizziness. As with any prescription medication, Abilify should only be taken under the supervision of a healthcare provider who can determine the appropriate dosage and monitor for potential side effects or interactions with other medications.
Some key points to consider when prescribing Aripiprazole include:
- Its unique pharmacologic profile, which includes partial agonism at several G-protein coupled receptors (GPCRs) [especially dopamine (D2) and 5-HT1A] and antagonistic action at others (especially 5-HT2A) 2
- Its efficacy in treating the positive and negative symptoms of schizophrenia, as well as manic or mixed states associated with bipolar I disorder 3
- Its relatively favorable tolerability profile, with a lower incidence of extrapyramidal symptoms and weight gain compared to some other atypical antipsychotics 4, 5
- Its availability in a long-acting injectable (LAI) depot formulation, which may be a valuable option for patients who are stable on oral aripiprazole but would prefer a less frequent dosing regimen 6
Overall, Aripiprazole (Abilify) is a valuable treatment option for patients with schizophrenia, bipolar disorder, and other conditions, and its use should be considered in the context of individual patient needs and circumstances.